City2Surf 2020
11 September 2020
Sydney's iconic Sun-Herald City2Surf 2020 is on Sunday 18 October 2020, it’s the 50th anniversary and this year the event is virtual, so more people can join in!
Hand sanitiser, social distancing, isolation, working from home…It’s all part of our ’new normal’. For events, the ‘new normal’ means a virtual event. It’s the perfect excuse to get a few mates together, enjoy the day and run, jog or walk 14kms in your neighbourhood to your own beat.
How does the virtual event work?
- Once you've registered you’ll receive an email with a link to download the C2S app
- Anytime between 6am and 6pm* on Sunday 18 October 2020, just open the C2S app and push ‘Start’. You’ll be tracked as if you're doing the actual C2S course - no matter where you are. (*MIA recommend avoiding the middle of the day when the UV rating is higher.)
- When you hit 14kms, the tracking will stop automatically, and your result will be submitted
- Be part of history! All finishers will receive C2S 50 year ‘bling’ (medal) and an exclusive 2020 bandana.
You’re invited to be a Charity Superstar!
Giving back to charity is the beating heart of City2Surf. Melanoma Institute Australia has 20 Charity Superstar places available to our fundraisers. We invite you to become one of 20 MIA Charity Superstars for this year’s City2Surf.
As a Charity Superstar you’ll be part of an exclusive group helping Melanoma Institute Australia achieve our mission of zero deaths from melanoma this decade. You’ll receive the following benefits:
- We’ll cover your C2S entry fee
- You’ll receive a ‘Run over Melanoma’ singlet, MIA hat and SunSense sunscreen
- Be part of the MIA and make a real difference for people impacted by melanoma
- Be rewarded for achieving your fundraising target of $1000 (we’ll support you!)
To apply to become a C2S Charity Superstar please click on the link below:
Together we can run over melanoma!
Visit the City2Surf website for more information about participating in this iconic event.
#City2Surf #LetsRunSydney #RunOverMelanoma.
High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
Monthly dose of immunotherapy allows flexibility for patients undergoing treatment
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
Australia's best minds in melanoma research converge on Melbourne
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
Nobel Prize for novel cancer therapies
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
World Health Organisation launches 4th edition of Classification of Skin Tumours
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Support PBS listing for pembrolizumab
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
World Congress on Cancers of the Skin 2018
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia welcomes new CEO Matthew Browne
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
Melanoma in Practice: Nurse Conference
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
Reducing the risk of melanoma in young adults
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia launches free e-learning education portal
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
David Day and a lifetime of missed moments
When David lost his life last year, he was 33, with three daughters under six.
Australian melanoma experts share latest breakthroughs with world's best oncologists
ASCO 2018 brings together the world's best in oncology from around the world.
ASCO 2018 – the important role of clinical trials
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
MIA Scoops Awards at the International Academy of Pathology
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Updated Clinical Guidelines for Melanoma
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
Melanoma and Marital Status: A Study
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
A weekend in Paris talking all things pathology...
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Our own 'Australian Story'
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.